Nature Communications (Nov 2021)
A potent and protective human neutralizing antibody targeting a novel vulnerable site of Epstein-Barr virus
- Qian-Ying Zhu,
- Sisi Shan,
- Jinfang Yu,
- Si-Ying Peng,
- Cong Sun,
- Yanan Zuo,
- Lan-Yi Zhong,
- Shu-Mei Yan,
- Xiao Zhang,
- Ziqing Yang,
- Yong-Jian Peng,
- Xuanling Shi,
- Su-Mei Cao,
- Xinquan Wang,
- Mu-Sheng Zeng,
- Linqi Zhang
Affiliations
- Qian-Ying Zhu
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC)
- Sisi Shan
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Diseases Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University
- Jinfang Yu
- The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University
- Si-Ying Peng
- Bejing IDMO Company Limited
- Cong Sun
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC)
- Yanan Zuo
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Diseases Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University
- Lan-Yi Zhong
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC)
- Shu-Mei Yan
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC)
- Xiao Zhang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC)
- Ziqing Yang
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Diseases Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University
- Yong-Jian Peng
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC)
- Xuanling Shi
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Diseases Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University
- Su-Mei Cao
- State Key Laboratory of Oncology in South China, Department of Cancer Prevention Research, Sun Yat-sen University Cancer Center (SYSUCC)
- Xinquan Wang
- The Ministry of Education Key Laboratory of Protein Science, Beijing Advanced Innovation Center for Structural Biology, Beijing Frontier Research Center for Biological Structure, Collaborative Innovation Center for Biotherapy, School of Life Sciences, Tsinghua University
- Mu-Sheng Zeng
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center (SYSUCC)
- Linqi Zhang
- NexVac Research Center, Comprehensive AIDS Research Center, Center for Infectious Diseases Research, Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University
- DOI
- https://doi.org/10.1038/s41467-021-26912-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 13
Abstract
Currently, there are no treatments or vaccines against Epstein-Barr virus (EBV) infection. Here, Zhu et al. isolate gH/gL-specific antibodies from infected donors and identify 1D8, that substantially reduces infection levels in both, B- and epithelial cells, and reduces tumor burdens in EBV-challanged humanized mice due to interferance with the gH/gL-mediated membrane fusion and binding.
